Beckley Psytech Limited, a private, clinical stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, announced today that Cosmo Feilding Mellen, Chief Executive Officer and Rob Conley, Chief Scientific Officer will be a panellist at Canaccord Genuity’s Symposium on New Paradigms and Treatment Approaches in Mental Health, taking place virtually on December 13th 2022. 

BPL-003 is Beckley Psytech’s patent-protected benzoate formulation of 5-MeO-DMT and is administered intranasally via an FDA-approved delivery device. In this study, BPL-003 was shown to be well-tolerated, with consistent dose delivery, highly reproducible pharmacokinetic profile and reliable induction of profound psychedelic experiences when dosed up to 12 mg in healthy participants. MHRA-approved Phase IIa studies of BPL-003 in Treatment Resistant Depression and Alcohol Use Disorder are expected to initiate in Q4 2022.

Beckley Psytech has dosed the first participant in their Phase I single-ascending dose (SAD) study of ELE-101, with top-line results expected in H1 2023. ELE-101 is a patent-protected, next-generation formulation of psilocin, the active metabolite of psilocybin, currently under clinical development for depression. ELE-101 is the second clinical-stage psychedelic compound in Beckley Psytech’s portfolio alongside BPL-003, the company’s lead candidate for upcoming MHRA-approved Phase IIa studies in depression and Alcohol Use Disorder (AUD).

Following on from last year, Beckley Psytech will again attend the Jefferies London Healthcare Conference and will hold a formal company presentation.

All equity acquisition adds short-acting psilocin candidate for broad range of indications to Beckley Psytech's portfolio of psychedelic assets. Expanded clinical pipeline will deliver multiple value inflection points over next 18 months. Phase 1 single ascending dose study of ELE-101 to initiate before the end of 2022. Lead 5-MeO-DMT formulation BPL-003 selected for upcoming Phase 2 studies in depression.